GENZ insisted their 2000L version of Myozyme was the same for more than two years, but finally admitted it was not the same, abondoned the application, then applied 4000L version of the drug, got approved as new drug Lumizyme.
These two situations are not the same. But it illustrates a point that you can't just listen to what a reputable company says. You have to draw inference from regulatory action and other sources.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.